Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Queensland Health
Fish and Richardson
Citi
Moodys
US Army
Argus Health
Farmers Insurance
Chinese Patent Office
UBS

Generated: October 21, 2017

DrugPatentWatch Database Preview

Janssen Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for JANSSEN PHARMS, and when can generic versions of JANSSEN PHARMS drugs launch?

JANSSEN PHARMS has fifty-six approved drugs.

There are thirty-seven US patents protecting JANSSEN PHARMS drugs and there have been three Paragraph IV challenges on JANSSEN PHARMS drugs in the past three years.

There are seven hundred and eighty-one patent family members on JANSSEN PHARMS drugs in fifty-seven countries and seventy-two supplementary protection certificates in fifteen countries.

Summary for Applicant: Janssen Pharms

International Patents:781
US Patents:37
Tradenames:54
Ingredients:34
NDAs:56
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms
TERAZOL 3
terconazole
SUPPOSITORY;VAGINAL019641-001May 24, 1988ABRXYesYes► Subscribe► Subscribe► Subscribe
Janssen Pharms
INVEGA
paliperidone
TABLET, EXTENDED RELEASE;ORAL021999-002Dec 19, 2006ABRXYesYes► Subscribe► Subscribe► Subscribe
Janssen Pharms
RAZADYNE
galantamine hydrobromide
TABLET;ORAL021169-002Feb 28, 2001ABRXYesNo► Subscribe► Subscribe ► Subscribe
Janssen Pharms
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER
levofloxacin
INJECTABLE;INJECTION020635-002Dec 20, 1996DISCNYesNo► Subscribe► Subscribe► Subscribe
Janssen Pharms
INVOKAMET XR
canagliflozin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL205879-001Sep 20, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Janssen Pharms
RISPERDAL
risperidone
TABLET;ORAL020272-002Dec 29, 1993ABRXYesNo► Subscribe► Subscribe► Subscribe
Janssen Pharms
CONCERTA
methylphenidate hydrochloride
TABLET, EXTENDED RELEASE;ORAL021121-001Aug 1, 2000ABRXYesNo► Subscribe► SubscribeY► Subscribe
Janssen Pharms
ORTHO-NOVUM 7/7/7-21
ethinyl estradiol; norethindrone
TABLET;ORAL-21018985-001Apr 4, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
Janssen Pharms
INVOKAMET
canagliflozin; metformin hydrochloride
TABLET;ORAL204353-003Aug 8, 2014RXYesNo► Subscribe► Subscribe ► Subscribe
Janssen Pharms
LEVAQUIN
levofloxacin
TABLET;ORAL020634-002Dec 20, 1996ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Janssen Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms
ORTHO-NOVUM 7/7/7-21
ethinyl estradiol; norethindrone
TABLET;ORAL-21018985-001Apr 4, 1984► Subscribe► Subscribe
Janssen Pharms
SPORANOX
itraconazole
INJECTABLE;INJECTION020966-001Mar 30, 1999► Subscribe► Subscribe
Janssen Pharms
CONCERTA
methylphenidate hydrochloride
TABLET, EXTENDED RELEASE;ORAL021121-002Aug 1, 2000► Subscribe► Subscribe
Janssen Pharms
RISPERDAL CONSTA
risperidone
INJECTABLE;INTRAMUSCULAR021346-003Oct 29, 2003► Subscribe► Subscribe
Janssen Pharms
SPORANOX
itraconazole
CAPSULE;ORAL020083-001Sep 11, 1992► Subscribe► Subscribe
Janssen Pharms
INVEGA SUSTENNA
paliperidone palmitate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022264-003Jul 31, 2009► Subscribe► Subscribe
Janssen Pharms
DITROPAN XL
oxybutynin chloride
TABLET, EXTENDED RELEASE;ORAL020897-001Dec 16, 1998► Subscribe► Subscribe
Janssen Pharms
TOPAMAX
topiramate
TABLET;ORAL020505-003Dec 24, 1996► Subscribe► Subscribe
Janssen Pharms
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER
levofloxacin
INJECTABLE;INJECTION020635-002Dec 20, 1996► Subscribe► Subscribe
Janssen Pharms
ULTRACET
acetaminophen; tramadol hydrochloride
TABLET;ORAL021123-001Aug 15, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for JANSSEN PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
canagliflozin
Tablets100 mg and 300 mg
INVOKANA
3/29/2017
canagliflozin andmetforminhydrochloride
Tablets50 mg/500 mg, 50mg/1000 mg, 150mg/500 mg, and150 mg/1000 mg
INVOKAMET
3/29/2017
rivaroxaban
Tablets10 mg, 15 mg, and 20 mg
XARELTO
7/1/2015
itraconazole
Oral Solution10 mg/mL
SPORANOX
5/3/2013
levofloxacin
Oral Solution25 mg/mL
LEVAQUIN
7/30/2009
norelgestromin and ethinyl estradiol
Transdermal System0.15 mg/0.02 mg per 24 hours
ORTHO EVRA
3/22/2007
galantamine hydrobromide
Extended-release Capsules16 mg and 24 mg
RAZADYNE ER
3/11/2006
galantamine hydrobromide
Extended-release Capsules8 mg
RAZADYNE ER
3/2/2006
almotriptan malate
Tablets6.25 mg and 12.5 mg
AXERT
12/8/2005
topiramate
Tablets50 mg
TOPAMAX
9/8/2005
topiramate
Capsules15 mg and 25 mg
TOPAMAX SPRINKLE
9/7/2005
methylphenidate hydrochloride
Extended-release Tablets18 mg*, 27 mg, 36 mg and 54 mg
CONCERTA
7/19/2005
metformin hydrochloride
Extended-release Tablets18 mg, 27 mg, 36 mg and 54 mg
CONCERTA
7/19/2005
risperidone
Orally Disintegrating Tablets0.25 mg
RISPERDAL
4/11/2005
risperidone
Orally Disintegrating Tablets3 mg and 4 mg
RISPERDAL
3/23/2005
galantamine hydrobromide
Tablets4 mg, 8 mg and 12 mg
RAZADYNE
2/28/2005
topiramate
Tablets25 mg, 100 mg and 200 mg
TOPAMAX
12/26/2001

Non-Orange Book Patents for Janssen Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,482,330Substituted fused heterocyclic C-glycosides► Subscribe
6,809,107 Neurotrophic pyrrolidines and piperidines, and related compositions and methods► Subscribe
7,511,022Substituted indole-O-glucosides► Subscribe
8,822,458Substituted oxazolidinones and their use in the field of blood coagulation► Subscribe
8,129,378Substituted oxazolidinones and their use in the field of blood coagulation► Subscribe
6,110,503 Preparation of biodegradable, biocompatible microparticles containing a biologically active agent► Subscribe
8,202,984Glucopyranoside compound► Subscribe
6,548,610 Method and apparatus for reducing static charges during polymerization of olefin polymers► Subscribe
6,905,654 Method and apparatus for reducing static charges during polymerization of olefin polymers► Subscribe
6,495,164 Preparation of injectable suspensions having improved injectability► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Janssen Pharms Drugs

Country Document Number Estimated Expiration
Canada2549025► Subscribe
Serbia20060323► Subscribe
China1419444► Subscribe
Taiwan200510440► Subscribe
African Intellectual Property Organization (OAPI)11740► Subscribe
South Korea20090086282► Subscribe
Serbia20060079► Subscribe
Canada2236691► Subscribe
Poland330530► Subscribe
New Zealand545304► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Janssen Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB95/028United Kingdom► SubscribePRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718
00521Netherlands► SubscribePRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006
C/GB06/022United Kingdom► SubscribePRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124
C/GB12/058United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
C/GB98/013United Kingdom► SubscribePRODUCT NAME: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE; REGISTERED: UK 00242/0314 19970923
842Luxembourg► Subscribe91842, EXPIRES: 20220512
C0051France► SubscribePRODUCT NAME: RIVAROXABAN; REGISTRATION NO/DATE: EU/1/08/472/001-008 20080930
0140011 00102Estonia► SubscribePRODUCT NAME: KANAGLIFLOSIIN;REG NO/DATE: K(2013)8171 (LOPLIK) 15.11.2013
/2015Austria► SubscribePRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
00670Netherlands► SubscribePRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131118
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Fish and Richardson
Accenture
Healthtrust
Argus Health
Dow
UBS
Colorcon
US Department of Justice
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot